Filing summary
Important identity discrepancy: The request identifies Newegg Commerce, Inc., but the supplied Form 10-Q is for Dehaier Medical Systems Limited, a medical-device company. It covers the quarter ended March 31, 2012. The figures below summarize the supplied filing and should not be attributed to Newegg without verification.
Business context and reporting period
Dehaier develops and distributes medical devices in China, including hospital equipment and respiratory and oxygen homecare products. It sells proprietary and third-party products primarily through distributors, with some direct sales to hospitals and government customers. Its unaudited results are for the three months ended March 31, 2012, compared with the same period in 2011.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $3.316 million | $2.953 million; up 12.3% |
| Gross profit / margin | $1.241 million / 37.43% | $0.997 million / 33.78% |
| Operating income | $454,820 | $298,368; up 52.4% |
| Net income | $130,615 | $209,744 |
| Net income attributable to Dehaier | $126,021 | $205,414 |
| Basic / diluted EPS | $0.03 / $0.03 | $0.05 / $0.04 |
| Operating cash flow | $(1.591) million | $(2.114) million |
Cost of revenue rose 6.1%, slower than revenue growth. Selling expense increased 32.9% to $318,679, while general and administrative expense declined 2.5% to $490,713. The filing attributes the stronger gross margin to improved operating effectiveness and inventory and cost management. Revenue from respiratory and oxygen homecare products rose to $391,630 from $209,005; medical-device revenue was $2.924 million versus $2.744 million.
Cash and cash equivalents fell to $2.299 million from $3.694 million at year-end 2011. Working capital was reported as $27.525 million. Current assets were $30.701 million and current liabilities $3.176 million. Short-term borrowings were $1.747 million, compared with $1.586 million at December 31, 2011. The company repaid $631,428 of bank loans and obtained $791,315 in new borrowing during the quarter. Investing cash outflow was $5,758; financing provided $159,887.
Material changes and unusual items
- Net income declined despite higher revenue and operating income, principally because the fair-value change in warrant liabilities produced a non-cash loss of $199,508 in Q1 2012, versus a $9,526 gain in Q1 2011. Management estimated Q1 2012 net income excluding these changes at $325,529, up 66.2% from $195,888.
- Operating cash use improved year over year, but remained substantial. The quarter included a $1.701 million increase in other receivables and a $1.493 million decrease in taxes payable, partly offset by inventory reductions and other working-capital movements.
- One customer represented approximately 27% of Q1 2012 revenue, compared with 18% a year earlier. The three top-selling products represented 81% of revenue, versus 90%.
- The company reported a $295,977 warrant liability at March 31, 2012. Warrants are valued using a Black-Scholes model and are classified as liabilities because the company’s functional currency is RMB while the warrants are indexed to its U.S.-dollar-traded shares.
Outlook, risks, and contingencies
Management said available working capital should fund anticipated needs and sustain current operations for at least 12 months. It provided no numerical revenue or earnings guidance. Plans include expanding homecare products and oxygen-therapy services, distribution channels, government-project participation, R&D, and overseas sales. Management said 2012 efforts for its Beijing home oxygen therapy service would focus on building the delivery network rather than generating significant revenue. It also cited possible inflation-driven cost increases and expected further selling and administrative spending.
Risks and items to monitor include customer and product concentration; collection of receivables, which generally carry 60–180 day terms and are largely unsecured; PRC policy and macroeconomic changes; and the renewal of BDL’s high-technology certification, due in September 2012, which supports its 15% income-tax rate. The filing says potential VAT liabilities related to certain customer returns were accrued, while estimated severance payments of approximately $276,000 were not recorded because management considered payment unlikely. BTL’s building secures bank borrowings, which are also guaranteed by BDL and a company officer. The company reported no legal proceedings and stated disclosure controls were effective, with no material quarterly changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Dehaier Medical Systems Limited’s 2012 Q1 report, not a Newegg filing.
- Reconcile the filing’s narrative statements about net income attributable to Dehaier with its financial statements; the statements report $126,021 for 2012 and $205,414 for 2011.
- Assess customer concentration, receivables collectability, and the increase in other receivables against the company’s operating cash use.
- Verify the warrant valuation and its effect on reported earnings, and monitor the high-technology tax certification renewal and any VAT matters.